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This study shows that the clinical performance and reproducibility of the cobas 4800 HPV test for high-risk
human papillomavirus (HPV) detection fulfill the criteria as formulated in international guidelines of HPV test
requirements for cervical screening purposes. Accordingly, the cobas 4800 HPV test can be considered
clinically validated for cervical screening.
A critical feature for high-risk human papillomavirus
(hrHPV) tests used for cervical screening is their clinical ac-
curacy for detection of high-grade cervical intraepithelial neo-
plasia (CIN) and cervical cancer (CIN2). For primary screen-
ing, an hrHPV test should have a balanced clinical sensitivity
and specificity to allow effective detection of CIN2 and min-
imize follow-up procedures of HPV test-positive women with-
out CIN2. Furthermore, high intra- and interlaboratory re-
producibility is required to ensure reliable performance of the
test in clinical practice. Both the high-risk HPV Hybrid Cap-
ture 2 method (HC2) and GP5/6-PCR-enzyme immunoas-
say (EIA) fulfill these specifications and are considered clini-
cally validated for screening purposes (4). In order to facilitate
the validation procedure of any novel, candidate hrHPV assay
without the necessity of performing large, prospective screen-
ing trials, specific criteria have recently been outlined by an
international consortium based on clinical equivalence analysis
(3, 4). Here, we evaluated the recently FDA-approved cobas
4800 HPV test (1) according to this validation strategy. The
cobas 4800 HPV test features automated sample preparation
combined with real-time PCR technology to detect 14 hrHPV
genotypes. PCR amplification and detection occur in a single
tube, where probes with four different reporter dyes track the
different targets in the multiplex reaction: (i) HPV16, (ii)
HPV18, (iii) 12 hrHPV types (i.e., HPV31, -33, -35, -39, -45,
-51, -52, -56, -58, -59, -66, and -68) as a pool, and (iv) -globin
as the control for extraction and amplification adequacy.
The clinical performance of the cobas 4800 HPV test was
assessed relative to HC2, which detects 13 hrHPV types (i.e.,
HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and
-68), in a cohort of screening participants originally screened
by cytology and HC2 cotesting (intervention group of the
VUSA-Screen trial) (5, 6). A detailed description of the
VUSA-Screen trial, including the referral policy and follow-up
procedure, has been published previously (6). Informed con-
sent was obtained from all study participants, and this study
followed the local ethical guidelines of the medical center.
A total of 860 archived cervical scrapings were selected com-
prising (i) a set for clinical sensitivity analysis of 60 represen-
tative scrapes from women (median age of 35 [range, 29 to 60]
years) who had histologically confirmed CIN2 (i.e., 23 with
CIN2, 33 with CIN3, 1 with adenocarcinoma, and 3 with squa-
mous cell carcinoma) diagnosed within a median follow-up
time of 3.3 (range, 0 to 32.6) months and detected through
either HC2 or cytology or both (hereafter referred to as cases)
and (ii) a set for clinical specificity analysis of 800 representa-
tive scrapes from women (median age of 45 [range, 29 to 61]
years) without CIN2 diagnosis within a median follow-up
time of 24.6 (range, 0 to 54.1) months (hereafter referred to as
controls). HC2 and cytology data of these scrapings were re-
trieved from the trial database. Of the cases, 17 (28.3%) had
normal cytology and 55 (91.7%) were HC2 positive. Of the
controls, 789 (98.6%) had normal cytology, 11 had a borderline
or mild dyskaryosis reading (i.e., equaling that of ASC-US
[atypical squamous cells of undetermined significance]/ASC-H
[atypical squamous cells, cannot rule out a high-grade lesion]/
LSIL [low-grade intraepithelial lesion]), and 45 (5.6%) had a
positive HC2 test.
Cervical scrapes (1/10 of the original sample) were used for
the cobas 4800 HPV test according to recommendations of the
manufacturer (Roche) in a blinded fashion, and results were
compared to HC2 data afterward. A valid cobas 4800 HPV test
result was obtained for all samples (Table 1). Of the cases, 54
(90%) had a positive cobas 4800 HPV test result. Of the con-
trols, the cobas 4800 HPV test gave a positive hrHPV result for
43 (5.4%) samples. Detailed cobas 4800 HPV test results are
given in Table 2. Agreement between the cobas 4800 HPV test
and HC2 was strong, i.e., 97.3% (778/800; 95% confidence
interval [95% CI], 95.9 to 98.2; kappa value, 0.74) and 98.3%
(59/60; 95% CI, 89.1 to 99.8; kappa value, 0.90) for controls
and cases, respectively.
Clinical sensitivity and specificity values of the cobas 4800
HPV test were compared to those of HC2 by using a nonin-
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feriority score test (software R), using a sensitivity threshold
for CIN2 of at least 90% and a specificity threshold for
CIN2 of at least 98% relative to that of HC2 (4). Both
clinical sensitivity and specificity for CIN2 of the cobas 4800
HPV test were noninferior to those of the HC2 using the
predetermined thresholds (P  0.022 and P  0.0009, respec-
tively). Whereas some minor differences at the analytical level
of HC2 and the cobas 4800 HPV test assays were seen (Table
1), these had no major impact on their clinical performances.
Our findings of comparable performance of the cobas 4800
HPV test and HC2 are in line with previous studies (2, 7).
To determine intralaboratory and interlaboratory agree-
ment of the cobas 4800 HPV test, 3 portions (1/10 of the
original sample each) of a set of 553 samples, 194 of which
tested positive by HC2, were independently subjected to the
cobas 4800 HPV test. The first two portions were tested within
the same laboratory (Lab A; VU University Medical Center
[VUmc]; Amsterdam, The Netherlands) at an interval of 8 to
10 weeks, and the third was tested in a different laboratory
(Lab B; Radboud University Nijmegen Medical Center, Ni-
jmegen, The Netherlands). Different assay lots were used in
the different laboratory settings.
The cobas 4800 HPV test displayed sufficient intralaboratory
reproducibility in time (Table 3) and interlaboratory reproduc-
ibility (Table 4). Both fulfilled the validation guidelines in that
the lower confidence bound of percentage of agreement was
higher than 87%, and the corresponding kappa value was
higher than 0.5 (4). Intralaboratory agreement as pointed out
by kappa statistics was higher than interlaboratory agreement.
It is difficult to find out what variable might be responsible for
this difference, since the cobas 4800 HPV test procedure in-
volves a sequence of several consecutive steps, including sam-
pling processing, DNA extraction, and real-time PCR analysis.
Since different lots of reagents were used in Lab A and Lab B,
these differences may simply reflect subtle differences between
different lots, though within acceptable limits. The cobas 4800
TABLE 2. Detailed results of the cobas 4800 HPV test in relation
to HC2 stratified by case/control status
Status cobas 4800 HPVtest result
No. of specimens
analyzed by Hybrid
Capture 2
that are HPV:
Total no. of
specimens
Negative Positive
Control (CIN2) HPV negative 745 12 757
HPV16 5 8 13
HPV18 0 3 3
Other hrHPV 5 16 21
HPV16 and
other hrHPV
0 3 3
HPV18 and
other hrHPV
0 3 3
Total 755 45 800
Case (CIN2) HPV negative 5 1 6
HPV16 0 24 24
HPV18 0 5 5
Other hrHPV 0 16 16
HPV16 and
other hrHPV
0 9 9
Total 5 55 60
TABLE 3. Intralaboratory agreementa
First-run
cobas 4800
HPV test
results
No. of scrapings in second run that
were hrHPV:
ND Total no. ofspecimens
Negative
Positive
HPV16b HPV18c OtherHPV
hrHPV negative 358 1 3 3 365
hrHPV positive
HPV16 positiveb 2 73 75
HPV18 positivec 1 16 1 1 19
Other HPV
positive
2 86 88
ND 3 2 1 6
Total 366 74 16 92 5 553
a Overall HPV test agreement (i.e., hrHPV positive/negative) of 98.3% (534/
543 specimens; 95% CI, 96.8 to 99.1). Kappa value of 0.96. Genotyping agree-
ment (i.e., HPV16, -18, other) of 98.2% (533/543 specimens; 95% CI, 97.1 to
99.3). Kappa value of 0.96. ND, not determined.
b Either combined or not combined with other hrHPV types.
c If combined HPV16/18 positive, the specimen is counted among HPV16
positives.
TABLE 1. cobas 4800 HPV test findings among 860 scrapings
collected in the baseline round in the VUSA-Screen trial,
stratified by case/control status
Status cobas 4800 HPVtest resulta
No. of specimens
analyzed by
HC2b that
are HPV:
Total no. of
specimens
Negative Positive
Control (CIN2) hrHPV negative 745 12e 757
hrHPV positive 10d 33 43
Total 755 45 800
Case (CIN2) hrHPV negative 5 1c 6
hrHPV positive 0 54 54
Total 5 55 60
a Sensitivity and specificity values of the cobas 4800 HPV test for CIN2 were
90% (54/60 specimens; 95% CI, 82.4 to 97.6) and 94.6% (95% CI, 93.0 to 96.2),
respectively.
b Sensitivity and specificity values of HC2 for CIN2 were 91.7% (95% CI,
84.7 to 98.7) and 94.4% (95% CI, 92.8 to 96.0), respectively.
c The discrepant result may relate to an initial workup failure. The leftover
cobas-extracted DNA of this sample also tested negative by the GP5/6-
PCR-EIA-reverse line blot (RLB) method (8), whereas both the cobas 4800
HPV test and GP5/6-PCR-EIA-RLB were positive on a renewed cobas
DNA extract of the original cervical scrape sample (i.e., positive for HPV16,
-18, and another type and positive for HPV16, -18, and -31, respectively). By
comparison, all double HC2/cobas 4800 HPV test-negative cases were nega-
tive by GP5/6-PCR throughout, both on the original cobas DNA extracts
and on extracts derived from an extra cobas DNA extraction procedure.
d Of the 10 HC2-negative/cobas 4800 HPV test-positive specimens, 8 (80%)
were hrHPV positive by GP5/6-PCR, and 2 were negative. Five of the 8
GP5/6-PCR-positive specimens revealed HPV16 alike the cobas 4800
HPV test, whereas three others contained HPV35, HPV45, and HPV66,
respectively. In the cobas 4800 HPV test, the latter three tested positive for
“other hrHPV.”
e Of the 12 HC2-positive/cobas 4800 HPV test-negative specimens, 7 were
positive following GP5/6-PCR-RLB for genotypes that could not be de-
tected by the cobas 4800 HPV test, i.e., HPV53 (n  1 specimen), HPV67
(n  1 specimen), and HPVlrX (n  5 specimens), and 3 were positive with
the hrHPV EIA probe but untypeable (HPVhrX). The remaining two sam-
ples were GP5/6-PCR positive for HPV52 (n  1 specimen) and HPV59
(n  1 specimen).
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HPV test provides HPV16 and -18 genotyping, which next to
the pooled hrHPV results turned out to be reproducible in this
study also (Table 3). Yet, the value of HPV16/18 genotyping in
screening is still a matter of debate.
In conclusion, the cobas 4800 HPV test fulfills all require-
ments as defined in the international guidelines (4) to consider
this assay clinically validated for screening purposes.
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TABLE 4. Interlaboratory agreementa
Lab A cobas
4800 HPV
test results
No. of scrapings in Lab B that were
hrHPV:
ND Total no. ofspecimens
Negative
Positive
HPV16b HPV18c OtherHPV
hrHPV negative 334 4 2 22 3 365
hrHPV positive
HPV16 positiveb 1 73 1 75
HPV18 positivec 19 19
Other HPV
positive
4 1 82 1 88
ND 4 2 6
Total 339 81 22 106 5 553
a Lab A, results from the first portion that was analyzed at VUmc; Lab B,
results from the third portion that was analyzed at the Radboud University
Nijmegen Medical Center. Overall HPV test agreement (i.e., hrHPV positive/
negative) of 94.6% (513/542 specimens; 95% CI, 92.4 to 96.2), with a kappa value
of 0.88. Genotyping agreement (i.e., HPV16, -18, other) of 93.7% (530/542
specimens; 95% CI, 91.7 to 95.7). Kappa value of 0.88. ND, not determined.
b Either combined or not combined with other hrHPV types.
c If combined HPV16/18 positive, the specimen is counted among HPV16
positives.
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